In the preclinical stage of the study vaccine COVID-19 received positive test results. On Thursday reported the German pharmaceutical company CureVac, noting that the leading candidate among the drugs on the role of the vaccine showed a positive result at a dose of only two micrograms.
“Data show a balanced immune response that is associated with the formation of large amounts of virus-neutralizing titers (VNTs) and T-cells. VNT is a key indicator that the drug can cause a strong immune response to neutralize the coronavirus”, – quotes RIA Novosti message of the company. In the summer, experts plan to begin clinical trials of this vaccine. Will be involved almost 100 volunteers.
Earlier it was reported that in the case of a mutation of the coronavirus may require multiple vaccines. This was stated by the doctor of medical Sciences, Deputy Director on scientific work of Institute of epidemiology of Rospotrebnadzor, Aleksandr Gorelov. He explained that it is likely in the future may require different vaccine strains from CОVID-19, like the flu.
